ADL Bionatur Solutions announced on Aug. 7, 2019, the signing of a strategic alliance with a new customer in Japan for active sterile pharmaceutical ingredients (APIs) production. The revenues of the contract with the undisclosed Manufacturer of pharmaceuticals, agricultural chemicals and veterinary drugs amounts to an initial amount of EUR 13 million over the next 5 years. ADL holds foreign manufacturer accreditations (FMA) from the PMDA (Pharmaceuticals and Medical Devices Agency of Japan) and MFDS (Ministry of Food and Drug Safety of South Korea), within others, and is an established partner for APIs production under sterile condition worldwide.